

# Satellite Meeting: C3 Glomerulopathy Program

<b>1130h-1135h</b>	Welcome and Introduction	Richard Smith
<b>Session One</b> <b>C3 glomerulopathy in 2019: <i>Where we are?</i></b>		Chair: Miquel Blasco
<b>1135h-1155h</b>	How we approach the condition and the patient in 2019 [Goal: present current diagnostic, evaluation and treatment strategies in the patient with native kidneys]	Marina Vivarelli
<b>1155h-1205h</b>	The current value of complement biomarkers in patient management [Goal: lightning talk on the current value of biomarkers in guiding clinical care]	Joshua Thurman
<b>1205h-1215h</b>	The challenges and outcomes of transplantation [Goal: present strategies used to determine whether/when to transplant in C3G]	Moglie Le Quintrec
<b>Session Two</b> <b>CAUSES: <i>An update on pathogenesis</i></b>		Chair: Elena Goicoechea de Jorge
<b>1215h-1225h</b>	What is new from the mouse models [Goal: Lightning talk on highlights from xxx mouse]	Kevin Marchbank
<b>1225h-1235h</b>	What's new from mouse models: the <i>C3del923_924DG</i> mouse [Goal: Lightning talk on insights from the <i>C3del923_924DG</i> mouse]	Santiago Rodriguez de Cordoba
<b>1235h-1250h</b>	Update on acquired factors: C3Nefs, antibodies and paraproteins – predicting outcome [Goal: present the values of C3Nefs (and stabilizing ability) and paraproteins in predicting renal outcome]	Sophie Chauvet
<b>1250h-1300h</b>	Complement in the native and transplant kidney [Goal: lightning talk on expected complement findings in normal and transplanted kidneys]	Nicholas Medjeral-Thomas
<b>1300h-1330h</b>	DISCUSSION of SESSIONS ONE and TWO Moderators: Miquel Blasco and Elena Goicoechea de Jorge	Panelists
<b>1330h-1430h</b>	<b>Lunch and Networking</b>	

<b>Session Three</b> <b>DIAGNOSIS: New insights</b>		Chair: Carla Nester
<b>1430h-1445h</b>	Influence of conventional immunosuppression in renal survival: insights from GLOSEN [Goal: present expected outcomes normal and transplanted kidneys]	Manuel Praga
<b>1445h-1500h</b>	Diagnostic Conundrums: do we need to refine the criteria to diagnose C3G? [Goal: MPGN/ICGN/MGRS]	Vivette D'Agati
<b>1500h-1515h</b>	Complement, immunoglobulins and paraproteins: the variable expressions of C3 glomerulopathy [Goal: Describe the broad spectrum of biomarker findings that fall under the rubric of C3G]	Veronique Fremeaux-Bacchi
<b>1515h-1530h</b>	Defining the clinical picture with complement biomarkers and assays [Goal: Describe the potential power of comprehensive complement testing to refine understanding of C3G]	Richard Smith
<b>1530-1600h</b>	DISCUSSION of SESSION THREE Moderator: Carla Nester	Panelists
<b>1600h-1630h</b>	<b>Coffee and Networking</b>	
<b>Session Four</b> <b>TREATMENT: Trials on trial</b>		Chair: Gerry Appel
<b>1630h-1650h</b>	The Doctor's dilemma: The plethora of clinical trials: what to do [Goal: Review the available trial options and describe the challenges and ethical obligations to patient treatment]	Beppe Remuzzi
<b>1650h-1710h</b>	The Patient's perspective: Living with C3 glomerulopathy – messages from the patients [Goal: Review the resources available to the patients and their expectations in clinical trials]	Lynne Lanning
<b>1710h-1730h</b>	Update on the trials [Goal: Describe the current status in the USA]	Carla Nester
<b>1730h-1800h</b>	DISCUSSION of SESSION FOUR Moderator: Gerry Appel	Panelists
<b>1800h-1825h</b>	PHARMA Panel Moderator: Gerry Appel	Panelists Representatives from Pharma
<b>1825h-1830h</b>	Final Thoughts and Conclusions	Richard Smith
<b>1830h</b>	<b>Meeting Close and Networking</b>	